Rationale: Nitrate-rich beetroot juice has been shown to improve exercise capacity in heart failure with preserved ejection fraction, but studies using pharmacological preparations of inorganic nitrate are lacking.
T he prevalence of heart failure (HF) with preserved ejection fraction (HFpEF) is rising. 1, 2 Recent tissue data demonstrate decreased cyclic GMP concentration, and increased oxidative stress in subjects with HFpEF, 3, 4 suggesting impaired nitric oxide (NO) signaling. However, efforts at increasing NO bioavailability, either through phosphodiesterase-5 inhibition or through the administration of organic nitrate, have not led to improvements in exercise capacity in HFpEF.
Traditionally, NO synthesis has been known to occur via the enzymatic oxidation of L-arginine by NO synthases, in the presence of molecular oxygen, to yield citrulline and NO. 7 Given its dependence on oxygen, NO synthesis from NO synthases may be inefficient in the setting of hypoxia. Inorganic nitrate, ingested in the diet or via supplementation, is rapidly absorbed in the gastrointestinal tract, concentrated in the salivary glands, and then released into the oral cavity where bacteria facilitate its reduction to nitrite. Nitrite is then reabsorbed into the circulation and can be reduced to NO by deoxyhemoglobin. 8 Conversion of nitrite to NO is potentiated by hypoxia and acidosis, 9, 10 as would be seen in exercising muscle, 11 leading to vasodilation and increased perfusion at sites of greater metabolic need. 12 Thus, circulating nitrate/nitrite may serve as an alternative pool for bioactive NO, which can sustain/enhance NO signaling when the traditional pathway for NO generation is less functional. 9, 13 Indeed, nitrate/ nitrite supplementation has been shown to increase blood flow to exercising muscle in rats with 14, 15 and without 16, 17 HF. NOinduced vasodilation during exercise may facilitate the matching of perfusion to metabolic activity. 18 Recently, our group demonstrated that acute supplementation with beetroot juice, which is rich in inorganic nitrate, improves vasodilatory reserve and peak oxygen uptake (VO 2peak ) in HFpEF subjects. 19 A more recent study demonstrated improvements in endurance during submaximal exercise after 1 week of supplementation with beetroot juice. 20 However, studies using pharmacological preparations of inorganic nitrate are lacking. The current study was an in-depth pharmacodynamic and pharmacokinetic study of oral potassium nitrate (KNO 3 ) in HFpEF subjects with the specific goals of (1) determining the safety profile of short-term (2 weeks) inorganic nitrate supplementation, administered as KNO 3 capsules; (2) determining the physiological effects and the dose-response associated with KNO 3 administration over 2 weeks on exercise capacity and key physiological adaptations to exercise; and (3) assessing the pharmacokinetic profile of KNO 3 in this population.
Methods Participants
Inclusion criteria included symptomatic HF in the context of a preserved (≥50%) ejection fraction. Subjects were required to have evidence of elevated filling pressures, demonstrated by at least 1 of the following: (1) elevated invasively measured filling pressures; (2) septal E/e′ >15; (3) septal E/e′ >8 with either elevated natriuretic peptide levels within the past year, left atrial enlargement, or chronic loop diuretic use for control of symptoms. Exclusion criteria included any rhythm other than sinus with native conduction, inability to exercise, more than or equal to moderate valvular disease, known hypertrophic/infiltrative/inflammatory cardiomyopathy, pericardial disease, current angina, acute coronary syndrome or coronary intervention within the past 2 months, primary pulmonary arteriopathy, clinically significant lung disease, current ischemia, chronic treatment with organic nitrates or allopurinol, significant liver disease, estimated glomerular filtration rate <30 mL/min per 1.73 m 2 or creatinine >2.5 mg/ dL, current smoking, alcohol dependency, Barrett's esophagus, G6PD deficiency, and a baseline methemoglobin >3%. Background medications were not altered. The study was approved by the Institutional Review Board of the University of Pennsylvania and conducted under a Food and Drug Administration Investigational New Drug Application (No 123 785). Written informed consent was obtained from all subjects. This study was registered on ClinicalTrials.gov (NCT02256345).
Study Medication and Dosing Regimen
This was a randomized trial of KNO 3 given in 2 dosing regimens: 6 mmol twice daily for 1 week followed by dose escalation to 6 mmol thrice daily for 1 week. Although a primary goal of the study was to assess the safety of KNO 3 and within-group changes in various end points in KNO 3 -treated subjects, a small number of placebo-treated (PB, n=3) subjects were included only to assess for any potential training effect on repeated exercise and Kansas City Cardiomyopathy Questionnaire (KCCQ) measurements. 21 Potassium chloride, given in equivalent doses, was used as the PB to account for differences in blood pressure or flow that could be attributed to potassium.
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Design
The study was initially designed to be single-blinded to allow the principal investigator to be aware of arm allocation because of 
Novelty and Significance
What Is Known?
• Heart failure with preserved ejection fraction (HFpEF) is associated with marked reductions in quality of life and exercise tolerance.
• Although nitric oxide bioavailability is reduced in HFpEF, prior efforts to increase nitric oxide using organic nitrate or phosphodiesterase-5 inhibitors have not been beneficial.
• Inorganic nitrate, which is reduced to nitrite by oral anaerobic bacteria, can increase nitric oxide signaling via selective reduction of nitrite to nitric oxide at the site of exercising muscle, leading to increased muscle blood flow.
What New Information Does This Article Contribute?
• Inorganic nitrate supplementation seems to be potentially safe and well-tolerated in HFpEF subjects.
• Inorganic nitrate supplementation increases exercise duration and quality of life in HFpEF subjects in a dose-dependent fashion.
• The benefits of inorganic nitrate in HFpEF subjects are most manifest at high exercise intensities.
We studied the population-specific safety and efficacy data for inorganic nitrate in HFpEF. We performed detailed phenotypic and pharmacokinetic assessments of inorganic nitrate in HFpEF. We found that a dose of ≤18 mmol/day of inorganic nitrate potentially seems to be safe, with dose-dependent improvements in exercise duration and quality of life. In contrast to organic nitrate therapy, inorganic nitrate did not reduce physical activity over the course of our 2-week study. These findings strengthen the rationale for performing a larger trial of inorganic nitrate in HFpEF patients.
potential concerns for methemoglobinemia with drug administration. As described later, however, no clinically significant elevations in methemoglobin occurred. One investigator (P. Zamani), who was the primary investigator responsible for supervising all visits and measurements during the study, remained blinded to treatment allocation throughout the entirety of the study. All physiological and imaging data were analyzed in a double-blind manner.
Study Protocol
Subjects presented to the Clinical and Translational Research Center at the University of Pennsylvania in the fasted state. Resting blood pressure was obtained using an automated oscillometric device (Accutorr Plus; Datascope Corp, Paramus, NJ). Blood was obtained for serum nitric oxide metabolites (NO m ) and nitrite determination, basic chemistries, and NT-proBNP (N-terminal pro b-type natriuretic peptide) determination (Cobas e411 Analyzer; Roche Diagnostics, Indianapolis, IN) and measurement of hemoglobin and methemoglobin (ABL800 Flex Analyzer; Radiometer America, Brea, CA). Subjects refrained from using mouthwash and were provided with a list of nitrate-rich foods to avoid during the study. A registered dietician met with subjects at each study visit to reinforce dietary restrictions. During the baseline visit (visit 1), subjects proceeded directly to the exercise testing protocol after verification of inclusion/exclusion criteria, a physical examination, echocardiography with arterial tonometry, and laboratory testing. During visit 2 and visit 3, study drug was administered with a standardized low-nitrate meal. Two hours later, orthostatic blood pressure measurements were made, followed by echocardiography, arterial tonometry, and the exercise protocol, as described later. The KCCQ was administered at each study visit.
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Echocardiography and Arterial Tonometry
Subjects underwent resting echocardiography using a GE Vivid I machine (GE Healthcare, Fairfield, CT). Metrics were quantified in triplicate according to the American Society of Echocardiography guidelines. 24 Left atrial volumes were quantified using the area-length method and indexed to body surface area. Left ventricular outflow tract Doppler velocity-time integrals were obtained from the 5-chamber view to obtain stroke volume (left ventricular outflow tract crosssectional area×velocity-time integral) at rest and at peak exercise.
Resting arterial tonometry (Millar Instruments, Houston, TX) was performed at the left radial artery and calibrated using brachial oscillometric blood pressures (Scholar III507EL; Criticare Systems, Inc, Waukesha, WI). Tonometric signals were processed using Sphygmocor software (AtCor Medical, Australia) to derive central pressures. Augmentation index was calculated as the ratio of the amplitude of the second peak to the first peak (P 2 /P 1 ×100%).
Exercise Studies
As described previously, 19 subjects underwent peak effort exercise testing using supine cycle ergometry with gas exchange measurements (Parvo Medics, Sandy, UT). VO 2,peak was defined as the average value obtained during the last 30 seconds of exercise. Exercise economy was estimated as the ratio of total work performed (kilojoules) to total oxygen consumed (liters) above baseline during the entirety of the exercise study. Prior work demonstrates an increased benefit for inorganic nitrate supplementation at higher exercise intensities when type II muscle fibers are used to a greater degree. 16, [25] [26] [27] [28] In post hoc analysis, we quantified total oxygen uptake and work performed during the last 3 and 6 minutes of exercise, when subjects were exercising at higher intensities, and obtained estimates of exercise economy over those time periods.
After at least 15 minutes of rest, subjects exercised at 25 W for 6 minutes with steady-state VO 2 measured during the final minute of exercise. Radial tonometry and left ventricular outflow tract velocity-time integrals were obtained at rest and during steady state to determine input impedance, as described previously. 29 VO 2 recovery kinetics (τ) was modeled according to a mono-exponential decay.
Skeletal Muscle Mitochondrial Oxidative Function
We used near-infrared spectroscopy to determine skeletal muscle mitochondrial oxidative function after a standardized exercise protocol, as described by Ryan et al, 30 and reported previously by our group.
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Safety and Pharmacokinetic Determination
On visit 1 and visit 2, subjects were given study medications (either 6 mmol KNO 3 or 6 mmol potassium chloride) with a standardized nitrate-free meal after exercise testing. For the next 5 hours, blood pressure was measured every 15 minutes, and serum was drawn every 30 minutes for determination of NO m and methemoglobin. The elimination rate (K e ) was the negative of the slope from the linear regression of log concentration versus time over the last 3 time points and used to calculate the half-life (t 1/2 =ln 2/K e ).
Serum NO m Quantification
Serum levels of NO m were measured as reported previously using vanadium (III)/hydrochloric acid reduction, heated at 95°C, and coupled with chemiluminescence detection using the Sievers nitric oxide analyzer (Sievers-NOA 280, Nitric Oxide Analyzer; Sievers Instruments, Boulder, CO). This method quantifies nitrate, as well as nitrite, NO-metal and heme complexes, low molecular weight thiol-NO adducts, and protein cysteine-NO adducts. 19 NO m samples for 3 individuals were repeated in each of the 9 batches performed. The intraclass correlation coefficient for NO m was 0.98 (95% confidence interval [CI] 0.93-1.00; P<0.001), demonstrating excellent reproducibility. Serum nitrite levels were quantified using reduction with potassium iodide/crystalline iodide and the same Sievers instrument. Nitrite samples were measured in each of the 6 batches performed. The intraclass correlation coefficient for nitrite was 0.94 (95% CI 0.77-1.00; P<0.001).
Activity Monitoring and 24-Hour Blood Pressure Measurements
At the conclusion of visit 1 and visit 2, subjects were given an ambulatory blood pressure monitor (Mobil-O-Graph PWA; I.E.M. GmbH, Stolberg, Germany) and an activity monitor (wActiSleep-BT Monitor; Actigraph, LLC., Pensacola, FL). Blood pressure measurements were obtained every 30 minutes over a 24-hour period. Actigraphy was used to obtain daily steps taken and estimated kilocalorie expenditure. Because follow-up visits were scheduled during the last 1 to 2 days of each week, data were abstracted for days 1 to 5 in all subjects. Values for days 3 to 5 were averaged to obtain estimates corresponding to steady-state drug effects.
Study Outcomes
The primary efficacy end point was the change in VO 2,peak . Secondary end points included changes in vasodilatory reserve (percent reduction in systemic vascular resistance during exercise, compared with the resting measurement), changes in mitochondrial oxidative function using near infrared spectroscopy, and changes in augmentation index. Exploratory end points included other metrics of exercise capacity and changes in the KCCQ. Pharmacokinetics was assessed via measurement of NO m after single-dose administration of 6 mmol and with trough levels after repeated twice daily and thrice daily administration.
Statistical Methods
Demographic data are presented as n (%) or means (SD). Mixedeffects models were generated in STATA (Stata/SE 13.1; StataCorp, College Station, TX), incorporating the correlation between repeated measurements in the same individual. No assumption of linearity was made. As prespecified in the protocol, only within-group comparisons were performed. Marginal means with 95% CI were determined from the mixed models and presented in the tables and figures. An overall P value <0.05 was taken to be significant for each model, with post hoc comparisons between visits performed subsequently. No adjustment for multiple comparisons was made. The elimination half-life was determined using the PK package in STATA. Linear regression was performed to assess the correlation between changes in serum NO m and nitrite levels and the change in exercise metrics. Regression coefficients are presented as standardized units describing the standard deviation change in the end point for each standard deviation change in the predictor variable. In a previous trial, we demonstrated a 1.0±1.2 mL/min per kg improvement in peak VO 2 after a single-dose (12.9 mmol) of inorganic nitrate, given in the form of beetroot juice. 19 Using a correlation between studies of 0.80, β=0.80, and α=0.05, we estimated that 7 subjects would be needed to demonstrate a similar change. We, thus, planned for 9 subjects in the active arm to allow for dropout. Randomization was performed by the University of Pennsylvania Investigational Drug Pharmacy. Randomization tables were constructed using a 3:1 KNO 3 :PB ratio in blocks of 4 (www.randomization.com).
Results
From 703 subjects screened, a total of 15 subjects were enrolled (Figure 1 ). An alternative explanation for dyspnea was identified during baseline testing in 3 individuals, who were subsequently excluded. Twelve individuals met all inclusion/ exclusion criteria and completed the study (Table 1) . Of these 12, 7 (58%) previously had elevated invasively determined intracardiac pressures. The remaining individuals had an elevated E/e′ ratio >8 along with at least 1 of the following: (1) an elevated NT-proBNP previously (n=1); (2) left atrial enlargement (n=1); (3) or the need for chronic loop diuretics for control of symptoms (n=3). Mean (SD) age of participants was 62.5 (5.8) years, 4 (33%) were males, and 3 (25%) were Black. Most participants had comorbidities typical for HFpEF: hypertension (100%), obesity (67%), hyperlipidemia (83%), diabetes mellitus (58%), obstructive sleep apnea (50%), coronary disease (33%), and chronic renal insufficiency (33%).
Maximal Effort Exercise Test
VO 2,peak , the primary efficacy end point, tended to increase, without reaching statistical significance (P=0.13). Vasodilatory reserve did not change with supplementation (P=0.72). The exploratory end point of exercise duration was significantly increased in the KNO 3 group (P=0.002; Table 2 and Figure 2 ). Both total work performed (P=0.02) and total oxygen uptake (P=0.019) increased. Additional hemodynamic data from the maximal effort study are presented in Online Table I . Interestingly, the change in VO 2,peak from the baseline to final visit correlated with the change in serum NO m levels: standardized β=0.74; P=0.006. The change in nitrite levels did not correlate with any metrics of exercise capacity.
In post hoc analysis, we evaluated oxygen uptake and work performed during the final 3 and final 6 minutes of exercise (ie, heavy and severe intensity). Work performed in the final 3 minutes increased significantly (P=0.002), as did total O 2 uptake in the final 6 minutes (P=0.041) and total work performed in the final 6 minutes (P=0.002; Figure 2 ). Overall, exercise economy in the final 3-minute (P=0.007) and 6-minute (P=0.004) periods increased (Online Table II ). The increase in oxygen uptake during the final 3 minutes of exercise correlated with the increase in serum NO m levels (standardized β=0.64; P=0.024).
Pharmacodynamics After Administration of 6 mmol of KNO 3
Blood pressure was measured every 15 minutes, and serum collected every 30 minutes, after the administration of 6 mmol of KNO 3 . The maximal reduction in systolic blood pressure (SBP) occurred at 3 hours and 45 minutes (−17.9 [95% CI −28.3 to −7.6] mm Hg; Figure 3 ). We observed a statistically significant, though clinically irrelevant, increase in methemoglobin, concurrent with the reduction in SBP (Figure 3 
Tolerability of KNO 3
KNO 3 was well tolerated, with all subjects completing the dosing and study protocols. Five individuals experienced side effects during the study (Online Table III ): 4 (44%) in the KNO 3 group and 1 (33%) in the PB group. Gastrointestinal symptoms and headache were the most common side effect. There were numerically fewer side effects in the KNO 3 group during week 2 (18 mmol/day of KNO 3 ). KNO 3 significantly increased fasting serum NO m concentration in a dose-dependent manner (Table 3) . This primarily reflects an increase in nitrate levels because nitrite levels did not change (data not shown). We observed a reduction in SBP with KNO 3 (Table 3) . Importantly, percent methemoglobin was no different between visits (Table 3) . Likely because of the serial blood sampling during the safety/pharmacokinetics portions of visit 1 and visit 2, hemoglobin was significantly reduced in the KNO 3 group (Table 3) .
Serum NO m , Blood Pressure, and Laboratory Testing at Each Visit
Orthostatic Blood Pressure Measurements
Orthostatic measurements were performed 2 hours after dose administration. Inorganic nitrate caused an asymptomatic reduction in SBP after 2 minutes of standing from a supine Elevated NT-proBNP (N-terminal pro b-type natriuretic peptide) defined as >125 pg/mL; eGFR calculated using the MDRD (modification of diet in renal disease) formula. ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CPAP, continuous positive airway pressure; eGFR, estimated glomerular filtration rate; LV, left ventricle; and NYHA, New York Heart Association. 
Kansas City Cardiomyopathy Questionnaire
The KNO 3 group experienced an improvement in HF symptoms over the 2-week study, as evidenced by higher scores on the KCCQ in several domains: symptom stability (P=0.03), symptom burden (P=0.049), total symptom score (P=0.016), and the functional status score (P=0.01; Figure 4 ). The overall summary score tended to improve with KNO 3 (P=0.067).
Resting Echocardiography
Diastolic function and left ventricular end-diastolic volumes were quantified at rest. Diastolic function was not affected by KNO 3 . Additionally, end-diastolic volume did not change (P=0.99; Online Table IV) . 
Oxygen Uptake and Input Impedance During Submaximal Exercise
Using radial tonometry and left ventricular outflow tract flow, input impedance was determined at rest and while at steady state during submaximal (25 W) exercise. No changes in input impedance were observed (Online Table V) . Neither steady state VO 2 (P=0.85) nor economy (P=0.98) were affected by KNO 3 (Online Table VI ). 
Augmentation Index and Mitochondrial Oxidative Function
There was no difference in augmentation index or mitochondrial oxidative function between visits in either the KNO 3 or the PB group (P=NS for all).
Lack of Training Effect in PB-Treated Subjects
There were no significant changes in any metric of exercise with PB. Furthermore, KCCQ scores did not change in these subjects during the course of the study, suggesting lack of a training effect on repeated testing. Data on study end points for the PB-treated subjects can be found in the Online Data Supplement (Online Table VII ).
Discussion
In subjects with HFpEF, the principal findings of this investigation are that KNO 3 (1) seems to be potentially safe at a dose of ≤18 mmol/day; (2) did not significantly improve the primary efficacy end point of peak VO 2 , although a nonsignificant trend was observed; (3) significantly increased the exploratory end point of exercise duration; (3) significantly improved several domains of the KCCQ; (4) did not worsen outpatient activity; and (5) this preparation demonstrates favorable pharmacokinetics, with high trough levels of NO metabolites achieved with doses of 6 mmol twice daily and substantially higher levels with thrice daily dosing, but without significant methemoglobinemia for either dosing interval. KNO 3 appeared to be potentially safe up to a dose of 18 mmol/day, and no subject prematurely discontinued study medications for any reasons. The side effects experienced were mild and were not more frequent at the higher dose. Similar to other studies, we demonstrate that KNO 3 mildly reduced resting blood pressure. 20, 31 We did, however, note a greater decrease in orthostatic SBP at the higher dose of 18 mmol/day, suggesting that this approaches the maximum tolerated dose. The reduction of nitrite to NO leads to the generation of methemoglobin, raising the theoretical concern for methemoglobinemia with KNO 3 administration. Consistent with this biology, we demonstrate a clinically insignificant rise in methemoglobin immediately after dose administration. However, there was no elevation in steady-state methemoglobin levels at any study visit, suggesting that the endogenous mechanisms of hemoglobin reduction operate fast enough to prevent any sustained rise in methemoglobin.
In contrast to NO production via NO synthases, which requires molecular oxygen, KNO 3 may provide an alternative source of NO that causes vasodilation and increased perfusion within hypoxic exercising muscle, leading to improved exercise duration. During our progressive ramp protocol, exercise duration increased via improved tolerance to heavy/severe exercise. As the intensity of exercise increases, a greater proportion of type II fibers is activated. 25 Type II fibers, with their lower capillary volume density and increased dependence on glycolytic pathways for ATP production, reside in a relatively more hypoxic and acidotic milieu, particularly during exercise, thus, providing an ideal environment for the reduction of nitrite to NO. 25 Our findings are in line with recent evidence for the preferential activation of nitrite by type II fibers 16 and at higher exercise intensities. [26] [27] [28] Participants randomized to KNO 3 experienced an improvement in HF-related symptoms, as evidenced by higher total symptom, symptom burden, and functional status scores. The total symptom score has previously been demonstrated to be the most responsive metric for the evaluation of HF symptoms, and lower functional status scores have been associated with an increased incidence of death or HF hospitalization. 23 Importantly, the magnitude of the changes seen in our study were generally >5 points, suggesting the potential for clinical relevance. 32 Given the substantial morbidity associated with HFpEF, 33 strategies that improve quality of life and exercise represent important progress for this patient population that has few therapeutic options. Beyond the short-term effects demonstrated in this trial, inorganic nitrate might enable HFpEF patients to better tolerate the initiation/maintenance of an exercise prescription, improving the adherence to, and efficacy of, an exercise regimen.
Recently, a randomized placebo controlled crossover study of an organic nitrate, isosorbide mononitrate, was performed in HFpEF patients. 5 This study demonstrated a reduction in physical activity with isosorbide mononitrate. In our study, no decrease in activity was identified, suggesting that KNO 3 may not have the same harmful impact.
Limitations
There are several limitations to our study. First, the sample size was small because a larger population could not be justified prior to assessing safety. Given the small number of patients exposed to active agent and the small number of placebo patients, the study had low power to detect safety signals. Gathering more robust safety data is a goal of the ongoing registered larger clinical trial that was supported by our present findings (KNO 3 CK OUT HFpEF trial [Effect of KNO3 Compared to KCl on Oxygen UpTake in Heart Failure With Preserved Ejection Fraction]; ClinicalTrials.gov: NCT02840799). Second, the pharmacokinetics portions of our study required serial blood draws, which caused a significant decrease in hemoglobin concentration from 13.6 to 12.8 g/dL (−5.9%). Because VO 2,peak is limited by oxygen delivery, particularly in HF subjects, 18 the decrease in hemoglobin may have constrained the increase in VO 2,peak and reduced the magnitude of the improvement in exercise capacity and quality of life. Indeed, in our current study, we found a 3.4% improvement in VO 2,peak . Had the hemoglobin remained constant, mathematically VO 2,peak would be expected to improve by ≈6%, leading to a similar magnitude of change as demonstrated in our prior study where a single acute dose of 12.9 mmol of inorganic nitrate improved VO 2,peak by ≈8%.
19 Differences in patient characteristics may also have contributed to the nonsignificant increase in VO 2,peak . Our prior study included a greater number of black males. It is conceivable that hypertensive blacks represent a unique population with particularly deranged NO synthases function 34 and stand to benefit more from interventions that increase NO bioavailability, as demonstrated in HF with reduced ejection fraction. 35 Furthermore, there may be differences in KNO 3 responsiveness between genders because females demonstrate less reduction in blood pressure after inorganic nitrate supplementation, despite greater increases in serum nitrate concentration. 36 Given the forced up-titration of study medications, we cannot exclude the possibility that the improvement in exercise duration was because of longer exposure to study medications versus the higher dose administered. That the change in VO 2,peak and oxygen uptake in the last 3 minutes of exercise correlated with the change in serum NO m levels suggests that the supplementation dose is also important. Additionally, we did not obtain serial urine and saliva samples during the pharmacokinetics segment of the study, precluding more detailed assessments. Finally, it is possible that more PB-treated subjects were needed to demonstrate a training effect; however, we were limited in the number of subjects to be performed in this initial pilot study. Our group is currently conducting a follow-up crossover study of KNO 3 versus PB in HFpEF subjects, which will be adequately powered to detect most relevant treatment-related differences and will also specifically address possible sex and race differences in the response to KNO 3 (KNO 3 CK OUT HFpEF trial; ClinicalTrials.gov: NCT02840799). KNO 3 improves exercise duration and quality of life in subjects with HFpEF. KNO 3 , at a dose of 18 mmol/day seems to be potentially safe with only mild reduction in blood pressure and no elevation in methemoglobin.
Conclusions
